Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC
Status:
Active, not recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, phase II clinical research study designed to assess
the safety and efficacy of nivolumab and ipilimumab in combination with paclitaxel in
patients with treatment naïve NSCLC.